Q-omics provides the consensus-scored PPFIA2 profile across patient tissues and cancer cell-line models. PPFIA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PPFIA2 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, PPFIA2 RNA expression shows 21,631 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRP, and PDAC as cancer lineages where PPFIA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPFIA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPFIA2 survival associations across molecular data types. PPFIA2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPFIA2 RNA expression–survival associations across cancer types. High PPFIA2 expression shows unfavorable associations in UVM, BLCA and KICH, but favorable associations in UCS, LUAD and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PPFIA2 RNA expression.
This table summarizes PPFIA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PPFIA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPFIA2 shows lower tumor expression in KIRP, KICH, LUSC, KIRC, BRCA and THCA. The KIRP box plot shows higher PPFIA2 RNA expression in normal versus tumor tissue (log2 FC = −0.458, t-test p < 0.001).
This table shows molecular features associated with PPFIA2 in patient tissues and cancer cell lines. In patient samples, PPFIA2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPFIA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
